

Role of oxidative stress in thyrotoxicosis

Geetha P A^{1*}, Ajaykumar B², Parvathi K³, Sreejayan M P⁴

{¹Additional Professor, Department of Biochemistry} {²Assistant Professor, ⁴Additional Professor, Department of Surgery} Government Medical College, Kozhikode, Kerala, INDIA.

³Professor, Department of Biochemistry, MES Medical College, Perinthalmanna, Malappuram, Kerala, INDIA.

Email: drgeethapa10@gmail.com

Abstract

Thyrotoxicosis is a clinical syndrome that results when excessive levels of active thyroid hormones T₃ and T₄ are secreted into the circulation. In thyrotoxicosis oxidative stress is implicated in the causation of clinical features like myopathy, myocardial insufficiency and ophthalmopathy. Oxidative change in thyrotoxicosis was assessed by measuring level of lipid peroxidation product malondialdehyde (MDA) and activity of antioxidant enzyme superoxide dismutase (SOD) in the blood of 18 thyrotoxic patients and 22 healthy euthyroid controls. Serum MDA level was significantly increased and serum SOD activity was very significantly decreased in the cases when compared to controls. **Conclusion:** The present study confirms the presence of oxidative stress in thyrotoxicosis. This warrants nutritional support with antioxidant agents in thyrotoxicosis.

Key Words: oxidative stress, thyrotoxicosis

*Address for Correspondence:

Dr. Geetha P A, Additional Professor, Department of Biochemistry, Government Medical College, Kozhikode, Kerala, INDIA.

Email: drgeethapa10@gmail.com

Received Date: 20/08/2017 Revised Date: 16/09/2017 Accepted Date: 01/10/2017

Access this article online	
Quick Response Code:	Website: www.statperson.com
	Volume 7 Issue 4

INTRODUCTION

Thyrotoxicosis is one of the most common afflictions involving the endocrine system. It is a clinical syndrome that results when excessive levels of active thyroid hormones T₃ and T₄ are secreted into the circulation¹. Both of these hormones have profound effect of increasing the metabolic rate in the body. Most of the clinical features of thyrotoxicosis is related directly to the increased metabolic activity caused by excess levels of thyroid hormones in the circulation¹. Clinical features include heat intolerance, weight loss, warm moist skin, anxiety, diarrhoea, tremor, cardiovascular manifestations like tachycardia and atrial fibrillation, proximal myopathy and ophthalmopathy². Most of these manifestations usually abate when a normal metabolic state is restored³ by the use of antithyroid drugs. But the clinical features

like myocardial insufficiency and ophthalmopathy are not fully amenable to antithyroid drugs. Their etiopathogenesis is also not well understood^{4,5,6}.

Oxidative stress in the pathogenesis of thyrotoxicosis: In hyperthyroidism excessive level of thyroid hormones are secreted to the circulation with a loss of normal feedback mechanism controlling the secretion of thyroid hormone. Thyroid hormones increase the metabolic activity of almost all tissues in the body. The basal metabolic rate can increase to 60-100% above normal when large quantities of hormones are secreted. The rate of utilization of food for energy is greatly accelerated. Increased metabolism due to hyperthyroidism leads to dysfunction of the mitochondrial respiratory chain, resulting in the generation of more reactive oxygen species like superoxide anion, hydrogen peroxide and hydroxyl radical¹¹. These potentially toxic free radicals cause increased lipid peroxidation damage to cellular membranes, mitochondrial damage, inhibit nucleic acid and inactivate cellular enzymes¹². This may be the cause of systemic manifestations like myopathy and myocardial insufficiency in thyrotoxicosis⁷. In vitro studies suggest a pathway through which oxygen free radicals may contribute to the retro-ocular fibroblast proliferation observed in patients with Grave's ophthalmopathy⁸. There is no satisfactory treatment modality to alleviate these features seen in thyrotoxicosis. Existing therapies for both thyrotoxic and the ophthalmopathic

manifestations are palliative in that they may relieve but do not cure the disease. At this state it is desirable to look to the oxidative state in thyrotoxicosis. In this study the oxidative status in thyrotoxicosis was assessed by comparing the levels of lipid peroxidation product malondialdehyde (MDA) and the activity of the antioxidant enzyme superoxide dismutase (SOD) between normal healthy euthyroid individuals and hyperthyroid patients.

MATERIALS AND METHODS

The patients for the present study were from the outpatients attending surgical OP of Govt. Medical College, Kozhikode. The present study was conducted on two groups consisting of 18 hyperthyroid patients and 22 age and sex matched healthy euthyroid controls

Exclusion Criteria

Smokers and patients clinically proven to have diabetes, coronary artery disease, renal diseases and hypertension which can alter MDA levels were excluded from the study. Thyroid function tests of each subject of both groups were done. Malondialdehyde was measured in serum by the method based on Valipasha and Sadasivadu's procedure for estimation of malondialdehyde¹³. The serum SOD activity was measured by the method suggested by Marklund and Marklund 1974 (Modified by Nandi *et al* 1988)¹⁴. Analysis was done in UV-Vis spectrophotometer 118 (Systronics).

Statistical Analysis

- Baseline parameters were compared using **Fischers exact test, Chi squared test** and **unpaired t test** (two tailed and assuming different SD).
- Comparison of evidence of oxidative stress between patients and control was performed using **unpaired t test** (one tailed and assuming different SD).
- **Correlation test** was performed using Spearman's correlation test (Non-parametric correlation test) to determine variation of evidence of oxidative stress with changing values of evidence of hyperthyroidism.

P value of <0.05 was considered significant. Values are expressed as numbers, percentage and mean \pm standard deviation.

RESULTS

Base line factors were compared between control and thyrotoxic patients – shown in table 1.

Table 1: Comparison of baseline factors

	Control (22)	Patients (18)	P value
Age	35.5 \pm 10.55	36.11 \pm 9.3	0.85
% male	8 (36.36%)	9 (50%)	0.58
Non-vegetarian	20 (90.91%)	15 (83.33%)	0.64
T ₃ (ng/ml)	1.31 \pm 0.28	3.19 \pm 1.31	<0.01
T ₄ (μ g/dl)	9.86 \pm 1.68	17.6 \pm 4.45	<0.01
TSH (μ IU/ml)	2.06 \pm 1.36	0.13 \pm 0.38	<0.01

Values expressed as mean \pm S.D and percentage Age, sex and non vegetarian status were comparable between the cases and controls. T₃, T₄ and TSH values showed significant difference between the cases and controls. Baseline characteristics of included thyrotoxic patients are shown in table 2.

Table 2: Baseline characteristics of included thyrotoxic patients

Total no. of patients	18 (100%)
% patients on antithyroid drugs	6 (33.33%)
% having exophthalmos	5 (27.78%)
% showing CVS manifestations	5 (27.78%)
% showing muscle weakness	5 (27.78%)

Comparison of evidence of oxidative stress between control and thyrotoxic patients are shown in table 3.

Table 3: Comparison of evidence of oxidative stress

	Control	Patients	P value
MDA (nmol/100ml)	50.87 \pm 9.7	59.68 \pm 16.02	0.03*
SOD (units/ml)	17.81 \pm 0.89	17.01 \pm 1.23	0.01**

Values expressed as mean \pm standard deviation, *Significant, ** Very significant

Evidence of oxidative stress with degree of hyperthyroidism was compared shown in table 4

Table 4: Comparison of evidence of oxidative stress with degree of hyperthyroidism (correlation value and P value)

	T ₃	T ₄
MDA – r (Pvalue)	-0.21 (0.39)	-0.42 (0.08)
SOD – r (Pvalue)	0.09 (0.73)	0.16 (0.54)

There is no significant correlation between MDA and, SOD with degree of hyperthyroidism.

DISCUSSION

Free radical mediated injury is suggested in the pathogenesis of myocardial insufficiency, myopathy and ophthalmopathy in thyrotoxicosis^{7,8,9}. The present study was conducted to assess the oxidative state in thyrotoxicosis by comparing the levels of lipid peroxidation product – malondialdehyde and the activity of antioxidant enzyme – superoxide dismutase between normal healthy euthyroid individuals and hyperthyroid patients. Baseline parameters were compared in both

study groups. Age, sex and non-vegetarian status can affect the oxidative status of individuals. As age advances the metabolic rate of the body decreases¹⁷. Metabolic rate has got influence on the oxidant stress of the individual. As metabolic rate increase, there is elevation in the oxidant stress of the individual. Male sex hormones increase the metabolic rate by about 10-15% and this can also affect the study¹⁷. In vegetarians due to the relatively increased intake of fruits and vegetables which are rich in antioxidants, the oxidative stress will be less in vegetarian when compared to non-vegetarians. In the present study, mean age, sex and non-vegetarian status ratio were comparable in both study groups. There was significant difference in T₃, T₄ and TSH values between the study groups. Serum MDA levels were significantly increased in hyperthyroid patients compared to euthyroid controls. Similar result was shown by the study conducted by Vikram Kesar *et al*⁷. Studies conducted by Bianchi G *et al*⁹, Komosiaska-Vassev *et al*¹⁰, Seven R *et al*¹⁸ and Guerra LN *et al*¹⁹ on serum of patients with Graves' disease also showed similar results. Increased metabolism due to the elevated levels of T₃ and T₄ in hyperthyroid individuals leads to the dysfunction of the mitochondrial respiratory chain, resulting in elevated formation of the reactive oxygen species like superoxide radical, hydroxyl radical which will cause increased lipid peroxidation damage to membranes of cells and sub cellular organelles which is evidenced by the elevation in MDA level. Serum superoxide dismutase activity was significantly decreased in thyrotoxic patients compared to controls. Similar study conducted by Vikram Kesar *et al*⁷ showed increased activity of intracellular SOD. Studies conducted on Graves' disease by Guerra LN *et al*¹⁹, Seven R *et al*¹⁸, Komosiaska-Vassev K *et al*¹⁰ and Hara H *et al*²⁰ showed increased activity of SOD compared to controls. Study conducted by Wilson R *et al* on Graves' disease showed decreased activity of SOD. Free radicals cause increased lipid peroxidation damage of cellular and sub cellular membranes, inhibits nucleic acids and protein synthesis and inactivate cellular enzymes¹⁶. The excessive generation of free radicals in thyrotoxicosis may be inactivating the enzyme systems in the body. This may be the cause of decreased SOD activity observed in the present study. Thyroid hormones induce or repress proteins by increasing or decreasing gene transcription. Very high concentrations of T₃ inhibit protein synthesis¹⁵. The decreased SOD activity observed in thyrotoxicosis can be due to the repressing effect of T₃ on SOD synthesis. To establish this further elaborate study is needed. No significant correlation was observed in the levels of MDA, and SOD with varying values of T₃ and T₄ in hyperthyroid patients. Hence T₃ and T₄ values

cannot be taken as predictors of degree of oxidant stress in hyperthyroid patients.

CONCLUSION

In the present study, the following results were obtained in thyrotoxicosis

- a) The level of lipid peroxidation product – Malondialdehyde is elevated.
- b) There is deficiency in the activity of antioxidant enzyme – superoxide dismutase in serum.
- c) There is no definite correlation between MDA, SOD activity with varying values of T₃ and T₄ in thyrotoxicosis.

The above data confirm the presence of oxidant stress in thyrotoxicosis. This warrants nutritional support with antioxidant agents which are defective in thyrotoxicosis. T₃ and T₄ values cannot be taken as predictors of degree of oxidant stress in hyperthyroid patients.

REFERENCES

1. Schwartz, Shires, Spencer, Daly, Fischer, Galloway. Principle of surgery, Seventh edition. Mc Graw Hill 1999, Vol.II, Pg. 1670.
2. S. Das. A concise text book of surgery. Second edition. 1999, Pg. 651-660.
3. Wilson, Foster, Kronenberg, Larson. Williams textbook of endocrinology. 9th edition, Pg 427.
4. Braunwald, Fauci, Kasper, Hauser, Longo, Jameson. Harrison's Principles of Internal medicine, 15th edition vol.II Pg. 2070.
5. Sabiston textbook of surgery. 15th edition Vol.I Pg. 612.
6. Wilson, Foster, Kronenberg, Larsen, Williams textbook of endocrinology. 9th edn. Pg. 435.
7. Vikram Kesar et al. Hyperthyroidism and the oxidative state in humans. Abstracts and Souvenir. 9th APCCB and 28th annual conference of ACBI. 11-14 March 2002. New Delhi, India. Pg.132.
8. Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS, Garrity J, Burman KD. Oxygen free radicals in interleukin-1 beta-induced glycosaminoglycan production by retroocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. 1999 Mar 9(3): 297-303.
9. Bianchi G, Solaroli E, Zaccheroni V, Grossi G, Bargassi AM, Melchionda N, Marchisini G. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism effect of treatment. Horn Metab Res 1999, Nov.31 (11): 620-4.
10. Komosiaska- Vassev K, Okzyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clinica Chimica Acta 2000 Oct. 300 (1-2): 107-17.
11. Komosiaska – Vasser K, Okzyk K, Winsz K. Free radicals 'Concepts in the etiopathogenesis of Graves-Basedow disease'. Post epy Hig Med Dosw. 2000; 54(2): 225-337.
12. Cederbaum AI. Role of lipid peroxidation and oxidative stress in alcohol toxicity. Free Rad Biol Med 1989; 7: 537-39.

13. Valipasha K and Sadasivudu B. Neuroscience Litt. 1984; 46: 209-214.
14. Marklund S, Marklund G (Modified by Nandi et al, 1988). Assay of superoxide dismutase activity in animal tissue. J Biochem 1988; 13(3): 305-15.
15. Daryl K Granner. Thyroid Hormones. Harper's Biochemistry. 25th Edn. 2000; 564-565.
16. Chawla A, Lavania AK. Oxygen toxicity. Medical Journal armed Forces India. 2001; 57: 131-3.
17. Guyton and Hall. Textbook of Medical Physiology. 10th Edn. Harcourt Publishers 2000; 820.
18. Seven R, Gelisgen K et al. Influence of prophythiouracil treatment on oxidative stress and nitric oxide in Basedow disease patients. J Toxicol Environ Health A. 2001 Apr.6; 62(7): 485-503.
19. Guerra LN, Moiguer S et al. Antioxidants in the treatment of Graves' disease. IUMB Life 2001; Feb.51 (2): 105-9.
20. Hara H, Ban V, Sato R. Serum superoxide dismutase in patients with Graves' disease. Nippon Naibunpi Gukkai Zasshi 1993; Feb.20; 69(2): 87-92.

Source of Support: None Declared
Conflict of Interest: None Declared